Stockreport

Insight Molecular Diagnostics: GraftAssureDX FDA Submission Warrants Hold Rating [Seeking Alpha]

Insight Molecular Diagnostics Inc.  (IMDX) 
PDF IMDX's decentralized GraftAssureDx aims to disrupt the $1B+ transplant rejection testing market, offering cost-effective, localized testing versus centralized lab compe [Read more]